First Drug to Help Reduce Allergic Reactions to Multiple Food Allergies, Tested at Children’s and Emory, Now FDA Approved

Children’s Healthcare of Atlanta and Emory University participated in a nationwide clinical trial showing that a 16-week course of omalizumab, an injectable drug, increased the amount of peanut, tree nuts, egg, milk and wheat that some multi-food allergic children as young as one year could consume without an allergic reaction after exposure.

CHOP Researchers Validate Pediatric “Allergic March” in Largest National Study of its Kind

In the largest study of its kind, researchers from Children’s Hospital of Philadelphia (CHOP) used electronic health record (EHR) data from more than 200,000 pediatric patients to describe patterns of pediatric allergies across the United States, validating a population-level pattern of allergy development known as the “allergic march,” in which allergies first present as eczema, followed by food allergies, asthma, and environmental allergies. The researchers also found that a rare food allergy called eosinophilic esophagitis (EoE), which has historically been considered a disease affecting primarily White males, is more common among non-White patients than previously reported.

Happy, Healthy Holiday Tips — Johns Hopkins Children’s Center Experts Available to Discuss Staying Safe and Healthy this Holiday Season

Navigating RSV, COVID-19 and the Flu   As more people travel and gather with family and friends this holiday season, cases of COVID-19, RSV and the flu are high and, in some areas, rising across the country. How can we keep…

NIH award to tackle early infant morbidity due to increasing incidences of food allergies

A Wayne State University School of Medicine researcher has been awarded a $1.93 million, five-year grant by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to study the impact of maternal immunoglobulin D (IgD) transferred to the fetus during pregnancy and its impact on protecting against food allergies.

New FDA-Approved Oral Immunotherapy Marks Important Milestone in Peanut Allergy Management

The U.S. Food and Drug Administration (FDA) approved Palforzia, a peanut powder product designed to help reduce peanut-induced allergic reactions.

Although Palforzia just received FDA approval, Nuvance Health allergists/immunologists have been offering oral immunotherapy (OIT) for various food allergies for five years.

By slowly increasing a person’s tolerance to an allergen over time, OIT can lower the risk of having a severe allergic reaction. This lowered risk may help reduce anxiety for kids with food allergies, as well as their family members and caregivers.